1231 related articles for article (PubMed ID: 17936563)
1. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
Park BH; Davidson NE
Cancer Cell; 2007 Oct; 12(4):297-9. PubMed ID: 17936554
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
4. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Wang Y; Liu Y; Du Y; Yin W; Lu J
Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
7. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
8. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
9. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
[TBL] [Abstract][Full Text] [Related]
10. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
[TBL] [Abstract][Full Text] [Related]
11. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Wang L; Zhang Q; Zhang J; Sun S; Guo H; Jia Z; Wang B; Shao Z; Wang Z; Hu X
BMC Cancer; 2011 Jun; 11():248. PubMed ID: 21676217
[TBL] [Abstract][Full Text] [Related]
12. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
[TBL] [Abstract][Full Text] [Related]
13. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
14. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Köninki K; Barok M; Tanner M; Staff S; Pitkänen J; Hemmilä P; Ilvesaro J; Isola J
Cancer Lett; 2010 Aug; 294(2):211-9. PubMed ID: 20193978
[TBL] [Abstract][Full Text] [Related]
15. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer--loss of PTEN predicts resistance to treatment.
Pandolfi PP
N Engl J Med; 2004 Nov; 351(22):2337-8. PubMed ID: 15564551
[No Abstract] [Full Text] [Related]
17. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
18. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
19. Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Russillo M; Di Benedetto A; Metro G; Ferretti G; Papaldo P; Cognetti F; Mottolese M; Fabi A
J Clin Oncol; 2011 Jul; 29(20):2834-5; author reply 2835. PubMed ID: 21670454
[No Abstract] [Full Text] [Related]
20. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
Hynes NE; Dey JH
Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]